273 related articles for article (PubMed ID: 20431291)
1. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Seminara P; Losanno T; Emiliani A; Manna G
Cardiology; 2010; 116(1):42-4. PubMed ID: 20431291
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine-induced hypertriglyceridemia: a report of two cases.
Koutras AK; Habeos IG; Vagenakis AG; Kalofonos HP
Anticancer Res; 2006; 26(3B):2249-51. PubMed ID: 16821596
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine-induced severe hypertriglyceridemia: report of two cases.
Kurt M; Babaoglu MO; Yasar U; Shorbagi A; Guler N
Ann Pharmacother; 2006 Feb; 40(2):328-31. PubMed ID: 16391007
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine-induced hypertriglyceridemia and hyperglycemia: two cases.
Duman BB; Paydas S; Tetiker T; Gunaldı M; Afsar CU; Erçolak V; Haksöyler V; Dilli MŞ
Pharmacology; 2012; 90(3-4):212-5. PubMed ID: 23038659
[TBL] [Abstract][Full Text] [Related]
6. Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine.
Geva S; Lazarev I; Geffen DB; Ariad S
J Chemother; 2013 Jun; 25(3):176-80. PubMed ID: 23783143
[TBL] [Abstract][Full Text] [Related]
7. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
Bar-Sela G; Haim N
Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
[TBL] [Abstract][Full Text] [Related]
8. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Petrioli R; Pascucci A; Francini E; Marsili S; Fiaschi AI; Civitelli S; Tanzini G; Battistelli S; Lorenzi M; Roviello F; Francini G;
Anticancer Drugs; 2008 Jan; 19(1):91-6. PubMed ID: 18043134
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
Weger W; Kränke B; Gerger A; Salmhofer W; Aberer E
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S4-6. PubMed ID: 18625380
[TBL] [Abstract][Full Text] [Related]
10. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
12. [Survey of the current status of capecitabine-induced hypertriglyceridemia].
Noguchi Y; Tsurushima M; Kawara H; Mitani T; Tokuyama Y; Uchiyama K; Shimizu Y
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1125-8. PubMed ID: 25248896
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine: an overview of the side effects and their management.
Saif MW; Katirtzoglou NA; Syrigos KN
Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
15. To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Nannini M; Nobili E; Di Cicilia R; Brandi G; Maleddu A; Pantaleo MA; Biasco G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):189-93. PubMed ID: 19151974
[TBL] [Abstract][Full Text] [Related]
16. Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature.
Han GH; Huang JX
J Oncol Pharm Pract; 2015 Oct; 21(5):380-3. PubMed ID: 24781450
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Do JE; Kim YC
Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
[TBL] [Abstract][Full Text] [Related]
18. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
19. [Breast cancer and the hand-foot syndrome].
Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine cardiac toxicity presenting as effort angina: a case report.
Lestuzzi C; Crivellari D; Rigo F; Viel E; Meneguzzo N
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):700-3. PubMed ID: 20093950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
